Omar Alkharabsheh, MD

home / authors / omar-alkharabsheh,-md

Articles

Omar Alkharabsheh, MD, USA College of Medicine

Dr. Alkharabsheh on Remaining Challenges in High-Risk CLL

Omar Alkharabsheh, MD
May 11th 2021

Omar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.

Read More

Omar Alkharabsheh, MD, discusses ongoing research with combination therapies for the treatment of patients with mantle cell lymphoma.

Dr. Alkharabsheh on Ongoing Research Efforts Examining Novel Combos in MCL

Omar Alkharabsheh, MD
May 10th 2021

Omar Alkharabsheh, MD, discusses ongoing research efforts examining combination therapies in patients with mantle cell lymphoma.

Read More

Dr. Alkharabsheh on Emerging Treatment Options in CLL

Dr. Alkharabsheh on Emerging Treatment Options in CLL

Omar Alkharabsheh, MD
May 5th 2021

Omar Alkharabsheh, MD, discusses emerging treatment options in chronic lymphocytic leukemia.

Read More

Omar Alkharabsheh, MD

Dr. Alkharabsheh on Future Research Directions in MPNs

Omar Alkharabsheh, MD
May 5th 2021

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Read More

Dr. Alkharabsheh on Novel Agents Under Exploration in Myelofibrosis

Dr. Alkharabsheh on Novel Agents Under Exploration in Myelofibrosis

Omar Alkharabsheh, MD
September 16th 2020

Omar Alkharabsheh, MD, discusses novel agents under exploration in the field of myelofibrosis.

Read More

Dr. Alkharabsheh on the Goals of Treatment in MPNs

Dr. Alkharabsheh on the Goals of Treatment in MPNs

Omar Alkharabsheh, MD
September 1st 2020

Omar Alkharabsheh, MD, discusses the current goals of treatment in myeloproliferative neoplasms.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need